Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 103.41 Million CHF | 1283.33% |
| 2022 | 7.47 Million CHF | 568.53% |
| 2021 | -1.59 Million CHF | -110.63% |
| 2020 | 15 Million CHF | -80.09% |
| 2019 | 75.37 Million CHF | 138.1% |
| 2018 | 31.65 Million CHF | 37.98% |
| 2017 | 22.94 Million CHF | 20.54% |
| 2016 | 19.03 Million CHF | 340.48% |
| 2015 | 4.32 Million CHF | 66.77% |
| 2014 | 2.59 Million CHF | 96.44% |
| 2013 | 1.31 Million CHF | -62.72% |
| 2012 | 3.53 Million CHF | 8.36% |
| 2011 | 3.26 Million CHF | -84.16% |
| 2010 | 20.6 Million CHF | 1154.35% |
| 2009 | 1.64 Million CHF | 3322.92% |
| 2008 | 48 Thousand CHF | -99.48% |
| 2007 | 9.22 Million CHF | 1081.31% |
| 2006 | 781 Thousand CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.05 Million CHF | 100.0% |
| 2024 Q1 | 7.05 Million CHF | -92.9% |
| 2023 Q2 | 3.93 Million CHF | 100.0% |
| 2023 Q3 | 49.71 Million CHF | 1162.21% |
| 2023 Q4 | 99.43 Million CHF | 100.0% |
| 2023 Q1 | 1.96 Million CHF | 61.04% |
| 2023 FY | 103.37 Million CHF | 1283.33% |
| 2022 Q4 | 1.22 Million CHF | 100.0% |
| 2022 Q3 | 611.5 Thousand CHF | -90.22% |
| 2022 Q2 | 6.25 Million CHF | 100.0% |
| 2022 Q1 | 3.12 Million CHF | 151.34% |
| 2022 FY | 7.47 Million CHF | 568.53% |
| 2021 FY | -1.59 Million CHF | -110.63% |
| 2021 Q4 | -6.08 Million CHF | -100.0% |
| 2021 Q1 | 2.24 Million CHF | -68.95% |
| 2021 Q2 | 4.49 Million CHF | 100.0% |
| 2021 Q3 | -3.04 Million CHF | -167.75% |
| 2020 Q1 | 3.88 Million CHF | -93.19% |
| 2020 Q2 | 7.77 Million CHF | 100.0% |
| 2020 Q3 | 3.61 Million CHF | -53.49% |
| 2020 FY | 15 Million CHF | -80.09% |
| 2020 Q4 | 7.23 Million CHF | 100.0% |
| 2019 Q3 | 28.53 Million CHF | 55.78% |
| 2019 FY | 75.37 Million CHF | 138.1% |
| 2019 Q2 | 18.31 Million CHF | 100.0% |
| 2019 Q1 | 9.15 Million CHF | 14.14% |
| 2019 Q4 | 57.06 Million CHF | 100.0% |
| 2018 Q4 | 8.02 Million CHF | 5.47% |
| 2018 FY | 31.65 Million CHF | 37.98% |
| 2018 Q3 | 7.6 Million CHF | -5.07% |
| 2018 Q2 | 8.01 Million CHF | 0.0% |
| 2018 Q1 | 8.01 Million CHF | 21.49% |
| 2017 Q2 | 5.42 Million CHF | 0.0% |
| 2017 FY | 22.94 Million CHF | 20.54% |
| 2017 Q4 | 6.59 Million CHF | 20.19% |
| 2017 Q3 | 5.48 Million CHF | 1.08% |
| 2017 Q1 | 5.42 Million CHF | -8.15% |
| 2016 FY | 19.03 Million CHF | 340.48% |
| 2016 Q4 | 5.91 Million CHF | 0.0% |
| 2016 Q3 | 5.91 Million CHF | 63.98% |
| 2016 Q2 | 3.6 Million CHF | 0.0% |
| 2016 Q1 | 3.6 Million CHF | 151.57% |
| 2015 Q4 | 1.43 Million CHF | 0.0% |
| 2015 Q2 | 727.5 Thousand CHF | 0.0% |
| 2015 FY | 4.32 Million CHF | 66.77% |
| 2015 Q1 | 727.5 Thousand CHF | -17.42% |
| 2015 Q3 | 1.43 Million CHF | 96.98% |
| 2014 Q1 | 414.5 Thousand CHF | 331.77% |
| 2014 FY | 2.59 Million CHF | 96.44% |
| 2014 Q4 | 881 Thousand CHF | 0.0% |
| 2014 Q3 | 881 Thousand CHF | 112.55% |
| 2014 Q2 | 414.5 Thousand CHF | 0.0% |
| 2013 Q2 | 563.5 Thousand CHF | 0.0% |
| 2013 Q1 | 563.5 Thousand CHF | -38.78% |
| 2013 FY | 1.31 Million CHF | -62.72% |
| 2013 Q4 | 96 Thousand CHF | 0.0% |
| 2013 Q3 | 96 Thousand CHF | -82.96% |
| 2012 Q3 | 920.5 Thousand CHF | 0.0% |
| 2012 FY | 3.53 Million CHF | 8.36% |
| 2012 Q4 | 920.5 Thousand CHF | 0.0% |
| 2011 FY | 3.26 Million CHF | -84.16% |
| 2010 FY | 20.6 Million CHF | 1154.35% |
| 2009 FY | 1.64 Million CHF | 3322.92% |
| 2008 FY | 48 Thousand CHF | -99.48% |
| 2007 FY | 9.22 Million CHF | 1081.31% |
| 2006 FY | 781 Thousand CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Addex Therapeutics Ltd | 1.61 Million CHF | -6294.68% |
| BB Biotech AG | -199.56 Million CHF | 151.819% |
| Basilea Pharmaceutica AG | 157.63 Million CHF | 34.396% |
| Evolva Holding SA | 9.43 Million CHF | -995.743% |
| Idorsia Ltd | 152.38 Million CHF | 32.137% |
| Kuros Biosciences AG | 33.56 Million CHF | -208.11% |
| Molecular Partners AG | 7.03 Million CHF | -1369.366% |
| Relief Therapeutics Holding AG | 6.03 Million CHF | -1614.139% |